SCHEMBL286952

SCHEMBL286952

O=C(O)Cc1ccc2c(c1)OCCO2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
RAB9A P51151 3/20 0.60
HTT P42858 2/20 0.60
HSD17B10 Q99714 2/20 0.60
HPGD P15428 2/20 0.60
USP2 O75604 1/20 0.60
LMNA P02545 1/20 0.60
GAA P10253 1/20 0.60
ALOX15 P16050 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C19 P33261 1/20 0.60
KDM4E B2RXH2 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPC1 O15118 1/20 0.55
TSHR P16473 3/20 0.54
PKM P14618 1/20 0.54
PTGDR2 Q9Y5Y4 1/20 0.54
PTGS1 P23219 1/20 0.52
PTGS2 P35354 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31409465 0.93 ALDH1A1 (0.57) ALDH1A1RAB9AHTTHSD17B10HPGD
SCHEMBL29642680 0.89 CYP3A4 (0.75) ALDH1A1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL3944098 0.89 CYP3A4 (0.75) ALDH1A1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL138875 0.89 CYP3A4 (0.75) ALDH1A1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL7332204 0.87 CYP3A4 (0.73) ALDH1A1RAB9AHPGDCYP1A2CYP3A4
Hydrochloric Acid SCHEMBL8838333 0.87 CYP3A4 (0.73) ALDH1A1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL1468159 0.87 ALDH1A1 (0.62) ALDH1A1RAB9AHTTHSD17B10HPGD
SCHEMBL3349791 0.86 ALDH1A1 (0.81) ALDH1A1RAB9AHTTHSD17B10HPGD
SCHEMBL13957312 0.86 ALDH1A1 (0.57) ALDH1A1RAB9AHTTHSD17B10HPGD
SCHEMBL5207755 0.84 ALDH1A1 (0.59) ALDH1A1RAB9AHTTHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5631038-A COMPOUNDS (TASTANDS) TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE ARE ADDED TO FOODS CONTAINING SODIUM CHLORIDE BIORESEARCH, INC. (US) 1997-05-20 US claimed
US-5631294-A PHENOXY- OR PHENYL-ALKANOIC ACIDS BIORESEARCH, INC. (US) 1997-05-20 US claimed
EP-0727151-A2 Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers BIORESEARCH, INC. (US) 1996-08-21 EP claimed
EP-0661932-A4 SPECIFIC EATABLE TASTE MODIFIERS. BIORESEARCH INC (US) 1996-06-05 EP claimed
CN-1029932-C Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers BIORESEARCH INC (US) 1995-10-11 CN claimed
EP-0661932-A1 SPECIFIC EATABLE TASTE MODIFIERS BIORESEARCH, INC. (US) 1995-07-12 EP claimed
WO-1993010677-A1 SPECIFIC EATABLE TASTE MODIFIERS BIORESEARCH, INC. (US) 1993-06-10 WO claimed
CN-1060770-A The sweetness inhibitor that contains substantially tasteless is as bitter inhibitor or contain the absorbed thing of the bitter inhibitor of substantially tasteless as sweetness inhibitor BIORESEARCH INC (US) 1992-05-06 CN claimed
WO-1991018523-A1 INGESTIBLES CONTAINING SUBSTANTIALLY TASTELESS SWEETNESS INHIBITORS AS BITTER TASTE REDUCERS OR SUBSTANTIALLY TASTELESS BITTER INHIBITORS AS SWEET TASTE REDUCERS BIORESEARCH, INC. (US) 1991-12-12 WO claimed
EP-0125049-B1 METHOD OF INHIBITING SWEETNESS TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1986-07-30 EP claimed
EP-0125049-A1 Method of inhibiting sweetness TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1984-11-14 EP claimed
WO-2026104679-A1 NOVEL SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-05-21 WO disclosed
EP-4734977-A2 NOVEL TRPV1 AGONISTS AND USES THEREOF Neucures, Inc. (US) 2026-05-06 EP disclosed
US-20260062399-A1 SUBSTITUTED ETHYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES ENVERIC BIOSCIENCES CANADA INC (CA) 2026-03-05 US disclosed
US-12492179-B2 Substituted ethylamine fused heterocyclic mescaline derivatives Enveric Biosciences Canada Inc. (CA) 2025-12-09 US disclosed
EP-0125049-B1 METHOD OF INHIBITING SWEETNESS TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1986-07-30 EP disclosed
US-4567053-A Method of inhibiting sweetness TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1986-01-28 US disclosed
EP-0128006-A2 A soil-disease-controlling agent SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1984-12-12 EP disclosed
EP-0125049-A1 Method of inhibiting sweetness TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1984-11-14 EP disclosed
US-4247597-A Electroscopic carrier particles having a carboxylic acid surface treatment PITNEY BOWES, INC. (US) 1981-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492179-B2 Substituted ethylamine fused heterocyclic mescaline derivatives DRD2, HTR5A, SLC18A2 ALDH1A1 402/4885RAB9A 798/4885HTT 1736/4885
US-20260062399-A1 SUBSTITUTED ETHYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES HTR1D, ADRA1D, CHRM1 ALDH1A1 219/4885RAB9A 362/4885HTT 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.